20/09/2014 14:01:32 Free Membership Login

Cannabis Science Reports Its First Documentary Release Date of April 5, 2012 “CHRONIC FUTURE - KILLING CANCER” A DOCUMENT...

Date : 03/27/2012 @ 2:03PM
Source : Business Wire
Stock : Cannabis Science, Inc. (QB) (CBIS)
Quote : 0.0556  -0.0044 (-7.33%) @ 4:30PM
Cannabis Science, Inc. (QB) share price Chart

Cannabis Science Reports Its First Documentary Release Date of April 5, 2012 “CHRONIC FUTURE - KILLING CANCER” A DOCUMENT...

Cannabis Science, Inc. (QB) (USOTC:CBIS)
Historical Stock Chart

3 Years : From Sep 2011 to Sep 2014

Click Here for more Cannabis Science, Inc. (QB) Charts.

Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is thrilled to announce that Muse Productions out of SCOTTSDALE, Arizona - announced today the Premier date of CHRONIC FUTURE - KILLING CANCER. The first of many Documentaries’ centering on the successful cancer treatments Cannabis Science has been reporting.

CHRONIC FUTURE - KILLING CANCER will premier on April 5th, 2012, at the Harkins Theater on Shea and Scottsdale Road in Scottsdale. Media are invited to the 5:00pm airing (limited seating) with a Q & A to follow. A VIP airing will start at 7:00pm. CRONIC FUTURE will remain in rotation through the month of April at this Harkins Theater.

CHRONIC FUTURE is a documentary created by Henry Miller and Cory Pritchard. It tells the story of Arizona’s Governor, Janet Brewer’s attempt to close down medical marijuana dispensaries and Allan Sobol, along with advocate attorney Tom Dean, fight to keep them. After the win in court, the story continues as it introduces patient after patient with debilitating ailment where medical marijuana healing ingredients have successfully treated the disease.

Perhaps the biggest revolution to this story is the apparent success and healing power that cannabis has when used to treat cancer patients. Cannabis Science (NASD OTCBB: CBIS) is a pioneering US biotech company that is developing pharmaceutical cannabis products. Cannabis Science has worked with 4 patients who administered Cannabis Science approved extracts to self-treat basal cell and squamous cell carcinomas (skin cancer).

The film covers everything from seed to success in the political and medical arena. As the unfortunate dark side the film also illuminates and exposes the story of how the government has avoided and covered up the successful medicinal use of marijuana, and decades of hypocrisy and misdirected messaging.

Photo-documentation on the Cannabis Science website (www.cannabisscience.com), shows that concentrated marijuana extract, topically applied to skin cancer, dramatically reduces the tumor burden and in some cases appears to have eliminated the cancer as confirmed by biopsy.

Dr. Melamede comments, "Chronic Future is a very important film. It highlights the extent to which prohibitionists are willing to impede the voice of American Citizens as expressed at the ballot box. How is it possible that our representatives in the various levels of government are allowed to get away actions that are undemocratic, and in fact treasonous. The documentary should outrage every American.”

The objective of the CHRONIC FUTURE documentary is to tell the truth about the benefits of medical marijuana, the government cover-up, and through the power of the media, reverse the negative stigma and propaganda the government has instilled in the public since the 1930s.

About Muse Productions:

Muse Productions is headed by Henry Miller. During the last six years of running his logistic company he wrote 35 script as well as wrote and directed three short films, one of which, “Rollers” won at the New York Film Festival.

Other projects of Muse Productions include a full feature film “Fix” about the rise and fall of a rock star featuring music from Guns and Roses, and “The Black Angels.”

About Dr Robert Melamede, PH.D:

Dr. Robert Melamede is the President & CEO of Cannabis Science Inc. and Associate Professor of Biology, University of Colorado, Colorado Springs, in one of the eleven states that allow the medicinal use of marijuana. Dr. Melamede is an expert on the biology of the cannabis plant, how it relates to the human endocannabinoid system, and why the cannabis plant has the potential to affect so many diseases and illnesses. Dr. Robert Melamede received his Ph.D. from the City University of NewYork. From there he became a Research Associate and Research Assistant Professor at New York Medical College and in 1989 he became a Research Assistant Professor at the University of Vermont. In 2001 he moved to the University of Colorado at Colorado Springs as an Associate Professor, and became the Chairman of the Biology Department until he retired as Chairman in the Fall of 2005. Dr. Melamede's expertise has been the repair of DNA damages caused by free radicals, the production of monoclonal antibodies via phage display, far from equilibrium thermodynamics as applied to biological systems, and pulling these all together, the endocannabinoid system. Additionally, Dr. Melamede is a founder of a small biotech company (Newellink) exploring novel cancer therapies.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. Our formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us 140920 14:01